Helus Pharma™ has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee. Dr. Lewis-Hall brings over 40 years of experience in clinical care, research, and biopharmaceutical leadership. She will provide guidance in clinical development strategy and regulatory engagement for Helus’ novel serotonergic agonist programs. Dr. Lewis-Hall’s appointment is subject to approval by Cboe Canada. Helus Pharma is focused on developing proprietary NSAs to address mental health conditions like depression and anxiety, with HLP003 in Phase 3 development for major depressive disorder and Breakthrough Therapy Designation from the FDA.

Read more at GlobeNewswire: Helus Pharma Appoints Former Pfizer Chief Medical Officer